10-Q quarterly report · filed Nov 12, 2026

Assembly Biosciences Inc (ASMB) Q3 2026 10-Q Quarterly Report

Short answer

Assembly Biosciences Inc (ASMB) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3M (down 72.6% year over year) with net income of −$20M.

Q3 2026 key financials · XBRL

Revenue
$3M
−72.6% YoY · −77.9% QoQ
Net income
−$20M
−120.3% YoY · −425.2% QoQ
Operating margin
-792.1%
EPS (diluted)
−$1.01
−94.2% YoY · −461.1% QoQ

Source: XBRL data from the Assembly Biosciences Inc (ASMB) Q3 2026 10-Q on SEC EDGAR. USD.

Assembly Biosciences Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 collaboration revenue $3.0M, down 73% YoY from $10.8M
  • Q3 R&D expenses $20.2M vs $16.6M YoY, driven by 6250 trial startups
  • Best program momentum: 6250 Phase 2 HDV dosing initiated; CLD Phase 2 planned for Q1 2027
  • Operating cash used $54.7M through September, cash and securities $314.3M at September 30
  • Outlook: funds expected to support operations into 2029, including Gilead’s $75.0M extension payment

Risk Factors

  • Newly added regulatory risk: FDA workforce downsizing and eliminated positions could delay inspections, reviews, guidance, and approvals
  • Most materially updated collaboration risk: Gilead declined 4334 licensing in March 2026, potentially slowing development and commercialization
  • Data privacy compliance risk: EU and UK GDPR violations can trigger fines up to €20 million, £17.5 million, or 4% of global revenue
  • Operational risk: Foreign CROs and suppliers face China scrutiny, tariffs, geopolitical disruptions, and supply-chain interruptions
  • Financial risk: Gilead owned approximately 24.4% of common stock and may increase ownership to 35%

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Assembly Biosciences Inc quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.